Life Sciences team advises Immedica Pharma AB on deal relating to pioneering bone marrow transplant treatment

International law firm Gowling WLG's Life Sciences team has advised Swedish pharmaceutical company Immedica Pharma AB ("Immedica") on a licence and supply agreement with Actinium Pharmaceuticals, Inc to commercialise Iomab-B, an Antibody Radiation Conjugate, that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies.

BMT is the only potentially curative treatment option for patients with active, relapsed or refractory acute myeloid leukaemia (AML).

Under the deal Immedica may potentially pay up to $452 million in milestone payments with royalties in the mid-twenty percent range Actinium received a $35 million upfront payment and Immedica obtained exclusive rights to Iomab-B in Europe, the Middle East and North Africa.

Patrick Duxbury (partner) led the legal team involved alongside Mathilda Davidson (legal director). The team worked with Immedica general counsel, Nina Fleck.

Commenting, Patrick said: "We are absolutely delighted to have assisted Immedica on this project and look forward to seeing the benefits of the treatment realised for patients."

With over 150 professionals in its Global Life Sciences Group, Gowling WLG has the technical understanding required to advise on the unique challenges companies face throughout their life cycles. They work with business, intellectual property, human resource and regulatory teams to provide guidance and support in key areas of life sciences.